YungShin Global Holding Corporation Investor Conference

Provide the best products to improve human health

Sep. 16, 2021

Disclaimers

This presentation is based on the information obtained from various sources which the Company believes to be reliable. But at some point in the future, there are a variety of factors which could cause actual results to differ materially from those statements. Therefore, please refer to the information on MOPS website as the main basis if any adjustment has been made. (http://mops.twse.com.tw/mops/web/index)

Table of Contents

Introduction of YungShin Group

A pharmaceutical Group have been established over 60 years, looking forward being a-century enterprise.

1952~1970	1970~1990	1990~2010	2010~2021

- 1952 Yungshin Pharmacy (Taiwan)

- 1965 Yung Shin(Taiwan)
- 1978 Yung Zip (Taiwan)
- 1985 Yung Shin(Hong Kong)
- 1987 Yung Shin(Malaysia)
- 1990 Carlsbad (U.S.A.)
- 1993 Listing of YSP
- 1994 Yung Zip (Shanghai) Yung Shin (Kunshan)
- 2000 Listing of YZC
- 2004 Yung Shin (Indonesia) YSP SAH (Malaysia)
- 2004 Listing of YSP SAH
- 2007 Yung Shin (Vietnam)
- 2011 YungShin Global Holding
- 2011 Listing of YSH
- 2013 Chemix (Japan)
- 2016 Vetnostrum (Taiwan)
- 2018 Listing (NEEQ) of YSK
- 2021 Promote to innovative layer of YSK

www.yungshingroup.com

Listing History

Four subsidiaries list in TW, CN and MY.

- 1993- Listing of Yungshin Pharmaceutical, Taiwan
- 2000-Listing of Yung Zip Chemical, Taiwan
- 2004-Listing of Y.S.P. Southeast Asia Holding, Malaysia
- 2011-Listing of YungShin Global Holding, Taiwan
- 2018-Listing (NEEQ) of Yung Shin Pharm.(Kunshan), China
- 2021 Promote to innovative layer

R&D and Production Planning Worldwide

Nine manufacturing and operating bases cross US, CN, JP and South Asia.

YungShin Group Main Production Bases(1/2)

Subsidiaries in TW, US and CN have been certified by USFDA. Production bases of YSG have covered 5 continents and products sold over 35 countries.

US Food & Drug Administration
FDA
APPROVED

1990
Yung Zip
(Taiwan)

永日化學
YUNG ZIP CHEMICAL

FDA

Australian Government
Department of Health
Therapeutic Goods Administration

Health Canada Santé Canada

BADAN POM RI

Pmda

衛 生 福 利 部
食 品 藥 物 管 理 署
FDA Taiwan Food and Drug Administration

1998
Carlsbad
(USA)

CARLSBADTECH
A world of innovative health products

FDA

2004
YungShin
(Taiwan)

永信藥品

FDA

HSA Health Sciences Authority

PPB Pharmacy and Poisons Board of Hong Kong

Health Canada Santé Canada

衛 生 福 利 部
食 品 藥 物 管 理 署
FDA Taiwan Food and Drug Administration

NATIONAL MEDICAL PRODUCTS ADMINISTRATION
国家药品监督管理局

2009
YungShin
(Kunshan)

永信藥品工業(昆山)股份
YUNG SHIN PHARM. IND. (KS)

FDA

YungShin

YungShin Group Main Production Bases(2/2)

MY, VN and IN sites have exported to Southeast Asia, middle East, North Africa and Oceania.

MY
(Malaysia)

VN
(Vietnam)

I N
(Indonesia)

αactive
(Malaysia)

NPRA MALAYSIA NATIONAL PHARMACEUTICAL REGULATORY AGENCY

Health Canada Santé Canada

Australian Government Department of Health Therapeutic Goods Administration

衛生福利部 食品藥物管理署 FDA Taiwan Food and Drug Administration

HSA Health Sciences Authority

香港藥劑業及毒藥管理局 PHARMACY AND POISONS BOARD OF HONG KONG PPB

BADAN POM RI

100% HALAL FOOD CERTIFIED HALAL

YUNGSHIN

永信

Operational Results for first half year of 2021

Provide the best products
to improve human health

YungShin

YSH Consolidated Statements of Income

Comparing Profit before income tax decreased by 12.20% and profit for the year decreased by15.58%% from Jan to Jun in 2021 and 2020.

(Expressed in millions of NTD)

	2021H1	2020H1	Growth rate
Operating revenue	3,698	3,926	(5.81)
Operating costs	(1,906)	(2,108)	(9.58)
Gross profit	1,792	1,818	(1.43)
Operating expenses	(1,339)	(1,312)	2.06
Income from operations	453	506	(10.47)
Non-operating income & Expenses	26	39	(34.62)
Profit before income tax	479	545	(12.20)
Profit for the period	361	429	(15.85)
Earnings per share	1.33	1.59	(16.35)

YSH Consolidated balance sheet (1/2)

Comparing total assets decreased by 1.85% from Jan to Jun in 2021 and 2020.

(Expressed in millions of NTD)

	2021H1	%	2020H1	%
Cash and cash equivalents	1,270	10	1,029	8
Inventories	3,030	25	2,816	23
Accounts receivable	1,614	13	1,735	15
Other current assets	440	4	519	3
Property, plant and equipment	4,346	36	4491	37
Other non-current assets	1,427	12	1,766	14
Total assets	**12,127**	**100**	**12,356**	**100**

YSH Consolidated balance sheet (2/2)

Comparing total shareholder's equity increased by 11% from Jan to Jun in 2021 and 2020.

(Expressed in millions of NTD)

	2021H1	%	2020H1	%
Short-term borrowings	1,991	17	2,396	19
Other current liabilities	1,722	14	2,429	20
Long-term borrowings	688	6	568	5
Non-current liabilities	793	6	717	5
Total shareholder's equity	6,933	57	6,246	51
Total liabilities and equity	**12,127**	**100**	**12,356**	**100**

YSH Consolidated Operating Revenue by area

Comparing consolidated revenue decreased 5.80% from Jan to Jun in 2021 and 2020.

(Expressed in thousands of local currency)

	Currency	2021H1	2020H1	Growth rate
Taiwan	TWD	2,507,316	2,702,072	(7.21)
USA	USD	10,902	10,527	3.56
China	CNY	149,573	147,850	1.17
Japan	JPY	886,775	998,446	(11.18)

1. The list the revenues of companies that YSH holding only more than 50% shares.
2. Operating revenue by area is based on financial report, and the growth rate is calculated in local currency.

Business Strategy

Provide the best products
to improve human health

Operating Strategy of YSH

Seven aspects to accomplish steady investment and pragmatic operation for creating the best interests of shareholders.

永信國際投控

A1 Unity & Communication

- YSH Strategy Committee
- Functional group

1. **Unity**： selfless sharing and support
2. **Mutual trust**： Appropriate information transparency
3. **Time accumulation, Results sharing**

A2 Quality, Production, Industrial Safety and Purchase

1. **United factory inspection annually**
2. **Functional group**
3. **Connect meeting**

A3 IT system sharing

1. **Administrative Operating** System
2. **Quality Control** System

B Investment & Operation

According to **the affiliate's investment amount and profitability** for segmental management：

1. Counseling period
2. Growth period
3. Maturity period

C1 Financial & Accounting

1. Evaluating **new investment**
2. Increase or decrease investment of affiliate according to operating results

C2 Legal Representative

Participating operation of affiliate and associate through legal representative appointment

D Talent Development

Middle and senior managers development

YungShin

Business Strategy of YSH

Internal investment management and external M&A for strengthening group efficiency

The strategy will balance short, medium and long term group development and shareholders' equity

Internal investment management

•**Production**
Cross company platform communication and production experience optimization

•**Marketing**
Search, supply, marketing promotion transnationally

•**Personnel**
Integrate experiences communication of joint factory inspection for national laws and regulations

•**R&D**
Project coordination, R&D technology transfer reducing investment

•**Finance**
Supervising by YSH, apply endorsement and guarantee to reduce financial burden and increase investment efficiency

External M&A

•**New business**

1. Obtaining factories, products and technologies and enter into the market of feed additives by merger and acquisition of Pfizer Inc.(Hsinchu plant)
2. Multi-angle consideration relating to health industry

•**New market**

1. Entering into OEM business by merger and acquisition of Alpha-Active and Taiwan Wa- Chein Ind. Co., Ltd.
2. New market evaluation such as in Europe…etc.

•**New product/technology**

1. Obtain manufacturing technology from GlyTech Inc.
2. Evaluating biological medicine, cell therapy and other fields.

Group Resource Breakthrough Global Market

Implant good experience to help penetrating local market



In house collect 2017

Maximize Value Chain Based on Product

Strengthen the competitiveness of the group through vertical integration and horizontal expansion

Maximize Value Chain

Vertical integration : Maximize Production Value Chain

- Vertical integration of main products through manufacturing and marketing of intermediate, API and FDF.
- Master raw material intermediate suppliers through investment and contract manufacture.
- Local production reduce the risk of trade barriers.
- Sharing R&D resource from in Taiwan and Malaysia lab.
- Continually strengthen product line competitiveness (integrate value chain and expand production batch size)

Horizontal expansion : Maximize Sales Value Chain

- Future product lines drive from market orientation
- Deep development of digestive tract, pain, hypersensitivity and anticancer fields.
- Increasing investment benefit through Integration product lines in various countries, mutual distribution, technology transfer, and development together.
- Expansion of four major business: API, FDF, OTC and animal drugs

Vertical Integration of Resources of YungShin

Continually strengthen vertical integration from API to FDF

永信國際投控 Strengthen vertical integration capabilities

	API (Active Pharmaceutical Ingredient)	FDF (Finish Dosage Form)	Market
Internal Strategy	Build second API production site or invest intermediate manufactory	Coordinate R&D, production and market strategies	Deepen cash cow market: Taiwan, Southeast Asia Develop world's major market: America, China, Japan, Europe
External strategy	Cooperation, Investment and Merger based on market value in pharmaceutical relative fields.		

YungShin Supply Chain Integration

Devoted to vertical integration from API, development, manufacturing to market



Response Methods of Coronavirus

Immediately response to make sure supply chain smoothly

Immediate information, Foresee risk, Respond in time, and Risk management

Risks:

1. Lockdown/Transportation is blocked
   a.Interruption of API supply(Import)
   b.Unable to export FDF (Export)

2. Personnel infection
   a.Operation of Company
   b.Influence of Production

Emergency response measures:

1. Cross-company Information sharing platform

2. Modify work rules of each companies (including but not limited to rules of going abroad, crowd gathering, Covid-19 prevention, and attendance)
   a.Government banned
   b.Necessary treatment of Company

3. Emergency measures of API inventory

4. Sharing solutions of API and transport cross company

Diversified Business Map

Expansion and exposure new business based on core health care relative business

永信國際投控

API
永日化學 YUNG ZIP CHEMICAL
Chemix Inc.
永信藥品
上海永日药品贸易有限公司
SHANGHAI YUNG ZIP PHARM. TRADING CO., LTD

CRO clinical trials

Small molecule prescription drugs
CARLSBADTECH
永信藥品工業(昆山)股份有限公司 YUNG SHIN PHARM. IND. (KS) CO., LTD.
Chemix Inc.
永信藥品
MY
VN
IN

Protein medicine

Cell therapy

Vaccine

OTC
永信藥品
MY

Functional food products
永信藥品
MY
αactive
永日化學 YUNG ZIP CHEMICAL
YUNGSHIN

Hospital test reagents
MY

Hospital Medical device
MY

Household medical device
MY

Laboratory equipment or consumables

Animal medicine
Vetnostrum

Feed additives
Vetnostrum

Pet health products
Vetnostrum

Core Value of YungShin Group

Provide the best products to improve human health from Taiwan

<u>Spirit of YungShin Group：</u>

We produce medicine that we would give it to our own families.

We establish Nursing Home that our elders would love to go to.

Social welfare covered by cooperate social responsibility

Thank you!

**Provide the best products
to improve human health**

www.yungshingroup.com